ALBO:NSD-Albireo Pharma Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 26.88

Change

+0.13 (+0.49)%

Market Cap

USD 0.52B

Volume

0.14M

Avg Analyst Target

USD 77.00 (+186.46%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Albireo Pharma Inc (ALBO) Stock Analysis:
Based on the Albireo Pharma Inc stock forecasts from 3 analysts, the average analyst target price for Albireo Pharma Inc is USD 77.00 over the next 12 months. Albireo Pharma Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Albireo Pharma Inc is Very Bearish, which is based on 0 positive signals and 3 negative signals. At the last closing, Albireo Pharma Inc’s stock price was USD 26.88. Albireo Pharma Inc’s stock price has changed by +1.06% over the past week, +4.35% over the past month and -26.19% over the last year.

About

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. Its lead product candidate is odevixibat, an ilea ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-19 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-12.54 (-6.72%)

USD83.01B 12.27 12.33
REGN Regeneron Pharmaceuticals Inc

+6.89 (+1.13%)

USD66.16B 9.84 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-0.23 (-0.10%)

USD59.51B 28.07 15.97
BNTX BioNTech SE

-7.57 (-4.47%)

USD47.53B 6.15 5.67
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

-2.78 (-1.16%)

USD24.70B N/A N/A
SGEN Seagen Inc

+2.26 (+1.73%)

USD23.82B 55.02 44.86
GMAB Genmab A/S

+0.30 (+0.87%)

USD23.35B 53.31 6.21
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A
ALNY Alnylam Pharmaceuticals Inc

-0.57 (-0.41%)

USD17.76B N/A N/A

ETFs Containing ALBO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 15.41% 97% A+ 97% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.41% 97% A+ 97% A+
Trailing 12 Months  
Capital Gain -26.19% 76% C 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.19% 76% C 35% F
Trailing 5 Years  
Capital Gain 40.07% 66% D 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.07% 66% D 52% F
Average Annual (5 Year Horizon)  
Capital Gain 14.86% 55% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.86% 55% F 60% D-
Risk Return Profile  
Volatility (Standard Deviation) 42.14% 69% D+ 41% F
Risk Adjusted Return 35.27% 65% D 53% F
Market Capitalization 0.52B 68% D+ 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.28 62% D- 51% F
Price / Cash Flow Ratio -5.18 49% F 68% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -24.33% 83% B 38% F
Return on Invested Capital -67.79% 33% F 12% F
Return on Assets -24.89% 50% F 15% F
Debt to Equity Ratio 5.31% 62% D- 78% C+
Technical Ratios  
Short Ratio 6.34 24% F 14% F
Short Percent 8.14% 25% F 21% F
Beta 1.40 42% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector